[WCHR 2026] New Hope for Alopecia areata: A Comprehensive Look at Research Trends in JAK Inhibitors

The keynote lecture on the second day was delivered by Angela M. Christiano (Columbia University, USA), who presented the research journey from uncovering the immune mechanisms of Alopecia areata to the development of JAK inhibitors.

The keynote lecture on the second day was delivered by Angela M. Christiano (Columbia University, USA), who presented the research journey from uncovering the immune mechanisms of Alopecia areata to the development of JAK inhibitors.

JAK inhibitors are immunosuppressive agents that inhibit Janus kinases (JAKs), enzymes involved in cytokine signaling. They were originally developed for the treatment of rheumatoid arthritis in adults. Cytokines are proteins that play important roles in the immune system, and JAK inhibitors regulate immune responses by blocking cytokine signaling pathways, making them effective treatments for autoimmune diseases such as rheumatoid arthritis.

As a result, interest grew in whether JAK inhibitors could also be effective for Alopecia areata, which is an autoimmune disease. In particular, JAK inhibitors were considered promising because they can suppress the JAK-STAT pathway, which is known to play a central role in Alopecia areata. Their safety profile had also been established through years of use in patients with rheumatoid arthritis.

Eventually, the U.S. Food and Drug Administration (FDA) approved JAK inhibitors for the treatment of severe Alopecia areata in adults. Approval for clinical use was subsequently granted in Korea, allowing the treatment to be used in clinical practice.

During her lecture, Angela M. Christiano (Columbia University, USA) received enthusiastic applause from the audience for her clear explanations of the immune mechanisms underlying Alopecia areata and the ways in which JAK inhibitors can act on these pathways, supported by a variety of illustrative figures.

A leading authority in dermatology and clinical molecular genetics, she has contributed significantly to both research and clinical practice by offering new perspectives on Alopecia areata through genetic discoveries and translational research approaches, including stem cell research and three-dimensional skin modeling.